| WANG Mo-pei,LI Hui-ping,ZHANG Zhao-hui.Clinical effect of 89SrCl2 in the treatment of breast cancer patients with bone metastasis[J].Chinese Journal of Radiological Medicine and Protection,2008,28(3):264-266 |
| Clinical effect of 89SrCl2 in the treatment of breast cancer patients with bone metastasis |
| Received:January 31, 2008 |
| DOI： |
| KeyWords:89SrCl2 Breastcancer Bonemetastasis Hematological toxicity |
| FundProject: |
| Author Name | Affiliation | E-mail | | WANG Mo-pei | Department of Chemotherapy and Radiation Medicine, Cancer Center, Third Hospital of Peking University, Beijing 100083, China | | | LI Hui-ping | Department of Chemotherapy and Radiation Medicine, Cancer Center, Third Hospital of Peking University, Beijing 100083, China | | | ZHANG Zhao-hui | Department of Chemotherapy and Radiation Medicine, Cancer Center, Third Hospital of Peking University, Beijing 100083, China | | | 张淑兰 | Department of Chemotherapy and Radiation Medicine, Cancer Center, Third Hospital of Peking University, Beijing 100083, China | | | 马力文 | Department of Chemotherapy and Radiation Medicine, Cancer Center, Third Hospital of Peking University, Beijing 100083, China | | | 贾廷珍 | Department of Chemotherapy and Radiation Medicine, Cancer Center, Third Hospital of Peking University, Beijing 100083, China | jiatingzhen@sina.com |
|
| Hits: 2593 |
| Download times: 1624 |
| Abstract:: |
| Objective To evaluate the clinical effect of 89SrCl2 as a palliative therapy for breast cancer patients with bone metastasis, and to observe the hematological toxicity induced by 89SrCl2 treatment. Methods 89SrCl2 dosage was 2.22 MBq/kg each time by intravenous for 51 patients. The analog scale, the cancer size and the hematological toxicity of 89SrCl2 treatment were observed. Results 17 patients (37.7%) among 45 patients became free of pain. The total pain relief rate was 84.4%.The response rate of metastatic sites was 62.7%. Approximately 76.5% of patients experienced neutropenia one month after theatment,whereas 62.7% of patients experienced thrombocytopenia. But the most of the patients could recover to the normal level 3 months after treatment. Conclusions 89SrCl2 is an effective and safe way for the pain relief and the life quality improvement in breast cancer patients with bone metastasis. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
